Demonstration Formulary
3 Respiratory system
03-04-03 Angioedema
| Dupilumab Dupixent® |
|
Formulary
|
 NICE TA751: Dupilumab for treating severe asthma with type 2 inflammation |
|
| Lanadelumab Takhzyro® |
|
Formulary
|
In line with NICE Highly specialist allergy centre- NHSE commissioned |
|
NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema |
|
|
| Berotralstat Orladeyo® |
|
Formulary
|
Use in line with NICE TA |
|
NICE TA738:Berotralstat for preventing recurrent attacks of hereditary angioedema |
|
|
Links
BCICB Asthma Treatment Guidelines - Adolescents 12-17 years old - BCICB Asthma Treatment Guidelines - Adults 18+
- BCICB Asthma Treatment Guidelines For Children Under 12
- BCICB COPD Inhaler Treatment Guidelines
- BCICB Difficult Asthma Referral Pathway - Adults 18+
- COVID-19: information for the respiratory community
- Greener Inhaler Guide Switching Information
- How to improve respiratory control in asthma and COPD
- NICE CG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE CG134: Anaphylaxis
- NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
- NICE TA138: Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over
- NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
- NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema
- NICE TA738:Berotralstat for preventing recurrent attacks of hereditary angioedema
- NICE TA751: Dupilumab for treating severe asthma with type 2 inflammation